Overview


According to FutureWise analysis the market for Anthrax Vaccines is expected to register a CAGR of 8.07% from 2023-2031.

Anthrax, caused by the bacteria Bacillus anthracis, is a rare but severe infection. It primarily affects farm animals, but humans can become infected through contact with contaminated animals or their products. BioThrax, or anthrax vaccine adsorbed (AVA), is the sole anthrax vaccine used. Unlike traditional vaccines, AVA doesn't contain live bacterial cells. Instead, it comprises a sterile solution derived from a filtered bacterial culture. This solution includes proteins the bacteria produce during its growth, including a crucial protein called protective antigen (PA). PA is a component of anthrax toxin, released by the bacteria during infection, which can lead to severe illness. AVA prompts the immune system to generate antibodies against the PA protein when administered. These antibodies play a crucial role in neutralizing anthrax toxins in the event of actual exposure to the disease. The vaccination schedule for AVA varies based on whether it's administered for prevention or post-exposure to anthrax.

However, specific individuals should not receive the anthrax vaccine, including those with a history of severe reactions to the vaccine or its components, those with weakened immune systems, pregnant women, individuals with prior anthrax disease, and those who are moderately to severely ill. The vaccine may also not be administered concurrently with specific immunosuppressive therapies.

FutureWise Market Research has published a report that provides an insightful analysis of Anthrax Vaccines Market trends that are affecting the overall market growth. This report will provide a detailed analysis of market share, regional insights, and competitor analysis that includes stature of key manufacturers operational in this industry. By the end of the forecast period FutureWise research analysts' projects that the Anthrax Vaccines Market will experience a significant growth. According to the analysis done, this report will help understand the information referring to the total valuation held by this industry. Additionally, this report will help in understanding the growth opportunities held by various segments of this market, further assist in making better strategic and expansion decisions by key stakeholders of an organization.

  • MerckCo., Inc.
  • Emergent Bio-Solutions
  • Zoetis, Inc.
  • PharmAthene, Inc.
  • Biogenesis Bago S.A.
  • Porton Biopharma Limited
  • Colorado Serum
  • Merial (a Sanofi Compayny)

(Note: The list of the major players will be updated with the latest market scenario and trends)

Recent developments by key players in the Anthrax Vaccines Market:

  • In October 2022, ICON plc was selected by (BARDA) the Biomedical Advanced Research and Development Authority in the Department of Health and Human Services (HHS), to conduct a clinical trial for an anthrax vaccine. The clinical evaluation of the AV7909 Anthrax vaccine is presently underway.

On the driver's side, the increasing global awareness regarding bioterrorism threats and the potential use of anthrax as a biological weapon have driven governments and healthcare organizations to invest in anthrax vaccines. Technological advancements in medical research and a growing understanding of anthrax biology have contributed to developing targeted vaccines to mitigate the severity of anthrax infections and improve patient outcomes. The need for preparedness in the face of bioterrorism incidents has prompted research and development in anthrax vaccines, resulting in advanced therapies. Moreover, the expanding base of laboratory workers, military personnel, and individuals working with animals at higher risk of anthrax exposure has necessitated the development and availability of effective treatment options, including vaccines and antitoxins. 
 
However, the market also encounters significant restraints. The complexities of manufacturing and distributing anthrax-specific treatment solutions, such as vaccines, pose challenges, as these products may have limited market demand outside emergencies. Regulatory hurdles associated with the approval process for anthrax vaccines, given the specialized nature of the condition, can also hinder the introduction of new products to the market. Moreover, concerns about the cost-effectiveness of investing in anthrax vaccines, especially compared to other healthcare priorities, may impact investment decisions and market growth.

By Vaccine Type

  • Cell-free PA Vaccines
    • Anthrax Vaccine Absorbed (AVA)
    • Anthrax Vaccine Precipitated (AVP)
  • Live Vaccines

By Application

  • Human Use
  • Animal Use

By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

By Region

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East and Africa

This market research report also emphasis on factors affecting the growth rate in various regions listed above. A deep-down analysis of the region will also be provided in the final version of this market, which is based on the conclusion of primary interviews and secondary data points gathered during the process.

By region, the market is segmented into North America, Latin America, Europe, Asia-Pacific, and Middle East & Africa. Asia-Pacific is projected to hold a significant share of the anthrax vaccine market over the forecast period due to the high burden of anthrax and the rising consumption of undercooked and raw meat in this region. The rise in the vaccination program to protect humans from the deadliest disease is expected to propel the market; expanded healthcare infrastructure and vital healthcare expenditure in this region are fuelling the demand. In addition, government initiatives and funds they raised for research and development are also driving the market. 

  • Tier 1 players- established companies in the market with a major market share
  • Tier 2 players
  • Emerging players which are growing rapidly
  • New Entrants
  • Growth prospects
  • SWOT analysis
  • Key trends
  • Key data-points affecting market growth
  • To provide with an exhaustive analysis on the Anthrax Vaccines Market By Vaccine Type, By Application, By Distribution Channel and By Region.
  • To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
  • To evaluate and forecast micro-markets and the overall market
  • To predict the market size, in key regions— North America, Europe, Asia Pacific, Latin America and Middle East and Africa.
  • To record and evaluate competitive landscape mapping- product launches, technological advancements, mergers and expansions
  • We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
  • The customization Mobility Care offered are free of charge with purchase of any license of the report
  • You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com

Table of Contents


  • 1.   Market Introduction
    •   1. Objectives of the Study
        2. Market Definition
        3. Market Scope
         3.1 . Years Considered for the Study
         3.2 . Market Covered
        4. Currency
        5. Limitations
        6. Stakeholders
  • 2.   Research Methodology
    •   1. Research Data
         1.1 . Secondary Data
          1.1.1 . Key Data from Secondary Sources
         1.2 . Primary Data
          1.2.1. Key Data from Primary Sources
        2. Market Size Estimation
        3. Market Breakdown and Data Triangulation
        4. Assumptions for the Study
  • 3.   Executive Summary
    •   1. Market Outlook
        2. Segment Outlook
        3. Competitive Insights
  • 4.   Anthrax Vaccines Market Variables, Trends and Scope
    •     1. Market LineProducts Outlook
        2. Penetration and Growth Prospect Mapping
        3. Industry Value Chain Analysis
        4. Cost Analysis Breakdown
        5. Technology Overview
        6. Regulatory Framework
         6.1. Reimbursement Framework
         6.2. Standards and Compliances

  • 5.   Market Overview
    •   1. Market Dynamics
         1.1. Market Driver Analysis
          1.1.1. Increasing focus of Anthrax Vaccines Companies on Brand Protection
          1.1.2. Untapped Opportunities in Emerging Regions
         1.2. Market Restraint Analysis
          1.2.1. High Cost Associated with Implementation of Predictive Analysis
         1.3. Industry Challenges
          1.3.1. Presence of Ambiguous Regulatory Framework
  • 6.   Anthrax Vaccines Market Analysis Tools
    •   1. Industry Analysis - Porter’s
         1.1. Supplier Power
         1.2. Buyer Power
         1.3. Substitution Threat
         1.4. Threat from New Entrants
         1.5. Competitive Rivalry
        2. Pestel Analysis
         2.1. Political Landscape
         2.2. Environmental Landscape
         2.3. Social Landscape
         2.4. Technology Landscape
         2.5. Legal Landscape
        3. Major Deals And Strategic Alliances Analysis
         3.1. Joint Ventures
         3.2. Mergers and Acquisitions
         3.3. Licensing and Partnership
         3.4. Technology Collaborations
         3.5. Strategic Divestments
        4. Market Entry Strategies
        5. Case Studies
  • 7.   Anthrax Vaccines Market, By Vaccine Type Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Cell-free PA Vaccines
         1.1. Anthrax Vaccine Absorbed (AVA)
         1.2. Anthrax Vaccine Precipitated (AVP)
        2. Live Vaccines

  • 8.   Anthrax Vaccines Market, By Application Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Human Use
        2. Animal Use

  • 9.   Anthrax Vaccines Market, By Distribution Channel Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Hospital Pharmacies
        2. Retail Pharmacies
        3. Online Pharmacies

  • 10.   North America Anthrax Vaccines Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. U.S.A
         2.2. Canada
         2.3. Mexico
        3. Market Size (USD Million) Forecast for North America 2023-2031

  • 11.   Latin America Anthrax Vaccines Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Brazil
         2.2. Venezuela
         2.3. Argentina
         2.4. Rest of Latin America
        3. Market Size (USD Million) Forecast for Latin America 2023-2031

  • 12.   Europe Anthrax Vaccines Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Germany
         2.2. U.K
         2.3. France
         2.4. Italy
         2.5. Spain
         2.6. Russia
         2.7. Poland
         2.8. Rest of Europe
        3. Market Size (USD Million) Forecast for Europe 2023-2031

  • 13.   Asia Pacific Anthrax Vaccines Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Japan
         2.2. China
         2.3. India
         2.4. Australia and New Zealand
         2.5. ASEAN
         2.6. Rest of Asia Pacific
        3. Market Size (USD Million) Forecast for Asia Pacific 2023-2031

  • 14.   Middle East and Africa Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. GCC
         2.2. Israel
         2.3. South Africa
         2.4. Rest of MEA
        3. Market Size (USD Million) Forecast for MEA 2023-2031

  • 15.   Market Share Analysis and Competitive Landscape
    •   1. Global Landscape - Key Players, Revenue and Presence
        2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3)
        3. Global Emerging Companies
        4. North America - Market Share Analysis and Key Regional Players
        5. Europe - Market Share Analysis and Key Regional Players
        6. Asia Pacific - Market Share Analysis and Key Regional Players
        7. Global Key Player - Growth Matrix
  • 16.   Company Profiles (Competition Dashboard, Competitors Deep Dive, Products Offered and Financial Layouts)
    •   1. MerckCo., Inc.
         1.1. Company Overview
         1.2. Product Portfolio
         1.3. SWOT Analysis
         1.4. Financial Overview
         1.5. Strategic Overview
        2. Emergent Bio-Solutions
         2.1. Company Overview
         2.2. Product Portfolio
         2.3. SWOT Analysis
         2.4. Financial Overview
         2.5. Strategic Overview
        3. Zoetis, Inc.
         3.1. Company Overview
         3.2. Product Portfolio
         3.3. SWOT Analysis
         3.4. Financial Overview
         3.5. Strategic Overview
        4. PharmAthene, Inc.
         4.1. Company Overview
         4.2. Product Portfolio
         4.3. SWOT Analysis
         4.4. Financial Overview
         4.5. Strategic Overview
        5. Biogenesis Bago S.A.
         5.1. Company Overview
         5.2. Product Portfolio
         5.3. SWOT Analysis
         5.4. Financial Overview
         5.5. Strategic Overview
        6. Porton Biopharma Limited
         6.1. Company Overview
         6.2. Product Portfolio
         6.3. SWOT Analysis
         6.4. Financial Overview
         6.5. Strategic Overview
        7. Colorado Serum,
         7.1. Company Overview
         7.2. Product Portfolio
         7.3. SWOT Analysis
         7.4. Financial Overview
         7.5. Strategic Overview
        8. Merial (a Sanofi Compayny)
         8.1. Company Overview
         8.2. Product Portfolio
         8.3. SWOT Analysis
         8.4. Financial Overview
         8.5. Strategic Overview

  • 17.   Pre and Post COVID-19 Impact
    •   1. Positive influence on the healthcare industry
        2. The financial disruption of the manufacturing sector
        3. Impact of COVID-19 on emerging companies
        4. Significant mandates in the healthcare regulations initiated by administrations
        5. The overall economic slowdown of the developing and developed nations
  • 18.   FutureWise SME Key Takeaway Points for Client
Partner

Our Clients